These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 10906743)
21. [Prostate cancer screening benefit very low, even after 13 years]. Blanker MH; Noordzij MA Ned Tijdschr Geneeskd; 2014; 158():A8349. PubMed ID: 25492737 [TBL] [Abstract][Full Text] [Related]
23. [Prostate cancer screening: Reasons of controversy]. Delporte G; Villers A; Penel N Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966 [TBL] [Abstract][Full Text] [Related]
24. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. Braillon A; Dubois G J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229 [No Abstract] [Full Text] [Related]
26. The prostate cancer conundrum. Albertsen PC J Natl Cancer Inst; 2003 Jul; 95(13):930-1. PubMed ID: 12837821 [No Abstract] [Full Text] [Related]
27. The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening? Auvinen A; Hugosson J BJU Int; 2003 Dec; 92 Suppl 2():14-6. PubMed ID: 14983947 [No Abstract] [Full Text] [Related]
28. Screening for prostate cancer. How can patients give informed consent? Marshall KG Can Fam Physician; 1993 Nov; 39():2385-90. PubMed ID: 7505673 [TBL] [Abstract][Full Text] [Related]
29. What should men know about prostate-specific antigen screening before giving informed consent? Chan EC; Sulmasy DP Am J Med; 1998 Oct; 105(4):266-74. PubMed ID: 9809686 [TBL] [Abstract][Full Text] [Related]
30. A misleading paper on prostate cancer screening. Elwood M Prostate; 2004 Dec; 61(4):372; author reply 373-4. PubMed ID: 15503318 [No Abstract] [Full Text] [Related]
31. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Andriole GL Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777 [TBL] [Abstract][Full Text] [Related]
32. [Early detection of cancer of the prostate. Pros and cons]. Hoesl CE; Altwein JE MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681 [TBL] [Abstract][Full Text] [Related]
33. Efficacy vs effectiveness in prostate-specific antigen screening. Albertsen PC J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583 [No Abstract] [Full Text] [Related]
34. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? Carroll PR; Whitson JM; Cooperberg MR J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396 [No Abstract] [Full Text] [Related]
35. Weighing the benefits and downsides of prostate-specific antigen screening. Pignone M Arch Intern Med; 2009 Sep; 169(17):1554-6. PubMed ID: 19786672 [No Abstract] [Full Text] [Related]